GleamWall
中文EN

RNLXY Renalytix plc

Services-Medical Laboratories · OTC · SEC CIK 1811115 · Fiscal year ends 06/30

Financial factors as of 2024-03-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.2%
TTM net income YoY5.5%
TTM EPS YoY30.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-1.6%
Operating margin-1,531.6%
Net margin-1,687.8%
FCF margin—
EBITDA margin-1,515.1%

Returns

ROE-1,073.2%
ROA-154.4%
ROIC (approx.)—
Asset turnover0.09x

Leverage & solvency

Liabilities / assets226.7%
Debt / equity—
Current ratio0.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-06-30FY20232023-06-30
Income statement
Revenue$2.29M$3.40M
Cost of revenue$2.13M$2.68M
Gross profit$156,000$720,000
R&D expense$9.29M$14.30M
SG&A expense$19.75M$28.66M
Operating income-$29.61M-$42.22M
Pretax income-$33.45M-$45.60M
Income tax$4,000$2,000
Net income-$33.46M-$45.61M
EBITDA-$29.24M-$41.71M
EPS (basic)-0.31-0.55
EPS (diluted)-0.31-0.55
Weighted avg. shares (diluted)108.18M82.21M
Balance sheet
Cash & equivalents$4.68M$24.68M
Receivables$722,000$776,000
Current assets$6.12M$26.88M
PP&E, net$216,000$1.03M
Intangibles$869,000$1.05M
Total assets$7.97M$30.63M
Current liabilities$11.49M$16.14M
Total liabilities$15.83M$23.66M
Shareholders' equity-$7.85M$6.97M
Shares outstanding154.37M93.78M
Cash flow statement
Operating cash flow-$30.11M-$34.09M
Capital expenditure—$0
Free cash flow—-$34.09M
Investing cash flow-$4,000$0
Financing cash flow$10.25M$16.39M
Depreciation & amortization$364,000$508,000
Stock-based compensation$1.71M$2.93M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.